BCL
LSBPW

Bracebridge Capital LLC’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Bracebridge Capital LLC’s Portfolio LSBPW Stock Details LSBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-232,323
Closed -$9.27K – 49
2025
Q2 		$9.27K Hold
232,323
– – ﹤0.01% 35
2025
Q1 		$9.57K Hold
232,323
– – ﹤0.01% 28
2024
Q4 		$18.4K Hold
232,323
– – ﹤0.01% 30
2024
Q3 		$15.4K Hold
232,323
– – ﹤0.01% 24
2024
Q2 		$20.4K Hold
232,323
– – ﹤0.01% 21
2024
Q1 		$16.6K Hold
232,323
– – ﹤0.01% 25
2023
Q4 		$8.83K Hold
232,323
– – ﹤0.01% 19
2023
Q3 		$9.57K Hold
232,323
– – ﹤0.01% 28
2023
Q2 		$10.9K Hold
232,323
– – 0.01% 32
2023
Q1 		$35.5K Buy
+232,323
New +$35.2K 0.01% 46

Other funds holding LSBPW

HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Bracebridge Capital LLC's LSBPW Position: Q3 2025 in Review

Bracebridge Capital LLC sold out of LakeShore Biopharma Warrants (LSBPW) in Q3 2025, closing a stake of 232,323 shares — an estimated $9.27K sold.

Bracebridge Capital LLC first reported a position in LSBPW in Q1 2023 and held it in 10 quarters. The position peaked at $35.5K in Q1 2023. 3 funds tracked by Wall St. Rank hold LSBPW as of Q3 2025.

  • Bracebridge Capital LLC reported no remaining LakeShore Biopharma Warrants position as of Q3 2025 after selling out during the quarter.
  • Bracebridge Capital LLC sold 232,323 LakeShore Biopharma Warrants shares in Q3 2025, an estimated $9.27K.
  • Bracebridge Capital LLC first reported a position in LakeShore Biopharma Warrants in Q1 2023 and held it in 10 quarters.
  • Bracebridge Capital LLC's LakeShore Biopharma Warrants position peaked at $35.5K in Q1 2023.
  • 3 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q3 2025.

Based on Bracebridge Capital LLC's 13F filing for Q3 2025, filed 14 Nov 2025.